Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 441,009 |
|
|||||
| News | - | ||||||
| Day High | 0.0098 | Low High |
|||||
| Day Low | 0.0065 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| CNBX Pharmaceuticals Inc (QB) | CNBX | OTCMarkets | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.0029 | -30.85% | 0.0065 | 15:30:13 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.00935 | 0.0065 | 0.0098 | 0.0065 | 0.0094 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 13 | 441,009 | US$ 0.007658 | US$ 3,377 | - | 0.0061 - 0.0487 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 14:28:47 | 275,771 | US$ 0.0065 | USD |
CNBX Pharmaceuticals Inc (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 311.11k | 17.03M | 4.20M | 410k | -3.71M | -0.12 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
CNBX Pharmaceuticals (QB) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/13/2024 | 15:27 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
| 1/12/2024 | 09:13 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 7/14/2023 | 09:28 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CNBX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.0084 | 0.0098 | 0.0065 | 0.0089355 | 126,127 | -0.0019 | -22.62% |
| 1 Month | 0.0099 | 0.013 | 0.0061 | 0.0102516 | 242,228 | -0.0034 | -34.34% |
| 3 Months | 0.0137 | 0.0175 | 0.0061 | 0.0114011 | 247,008 | -0.0072 | -52.55% |
| 6 Months | 0.01365 | 0.01835 | 0.0061 | 0.0124024 | 254,844 | -0.00715 | -52.38% |
| 1 Year | 0.026 | 0.0487 | 0.0061 | 0.019301 | 376,880 | -0.0195 | -75.00% |
| 3 Years | 0.1875 | 5.50 | 0.0061 | 0.0481166 | 258,909 | -0.181 | -96.53% |
| 5 Years | 0.31 | 5.50 | 0.0061 | 0.1560572 | 267,466 | -0.3035 | -97.90% |
CNBX Pharmaceuticals (QB) Description
| CNBX Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company specializing in the discovery, development and commercialization of novel cannabinoid-based products and innovative technologies for the treatment of cancer. We combine the power of our proprietary technologies with the expertise of our leading scientists to unlock the medicinal properties of cannabis and its diversity of bioactive compounds. We have conducted thousands of tests on biopsies and cell lines in order to identify the physiologic impact of cannabinoids on cell cycle and cell death. Our core technology is a continuously evolving bioinformatics platform that utilizes high throughput screening technology, advanced data analytics, artificial intelligence and proprietary methodologies to rapidly examine the physiologic impact of multiple cannabinoid compounds on tumor cells. |
